Tanezumab Biosimilar - Research Grade

Human

NGF

>1mg/ml

Human IgG2(A330S/P331S)-Kappa

Fasinumab Biosimilar - Research Grade (ICH5152), Fulranumab Biosimilar - Research Grade (ICH5157), Bedinvetmab Biosimilar - Research Grade (ICH5380), Izenivetmab Biosimilar - Research Grade (ICH5615), Luvagrobart Biosimilar - Research Grade (ICH5665), Ranevetmab Biosimilar - Research Grade (ICH5805)

https://www.imgt.org/mAb-DB/

ICH3002

P01138

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of tanezumab, a humanized monoclonal antibody directed against nerve growth factor (NGF), supplied strictly for research use only. It reproduces the antigen-binding specificity of the originator molecule but is manufactured as a laboratory reagent rather than a clinical drug, and it is not intended for human or veterinary use. The molecule is built around the NGF target and carries a human IgG2 framework with A330S/P331S substitutions that reduce Fc effector engagement, making it useful as a clean binding and neutralisation tool. Researchers use this analog as a positive control and benchmarking reagent in ligand-blocking assays, in NGF/TrkA signalling studies, in comparability and bioanalytical method development (including anti-drug-antibody and pharmacokinetic assay standards), and as a starting reagent for ADC or engineering workflows. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), in bulk milligram-to-gram quantities suitable for in-vitro and preclinical experimentation. No clone identity is implied or specified. Nerve growth factor (NGF; UniProt P01138) is the prototypical neurotrophin, secreted as a precursor (proNGF) and processed to a mature 118-amino-acid beta subunit that functions as a non-covalent homodimer. NGF signals through two receptors: the high-affinity receptor tyrosine kinase TrkA (NTRK1), which drives neuronal survival, differentiation and neurite outgrowth via Ras-MAPK, PI3K-Akt and PLCgamma pathways, and the low-affinity p75 neurotrophin receptor (p75NTR), which can modulate affinity or trigger apoptotic signalling. NGF is essential for the development and maintenance of sympathetic and sensory neurons and basal-forebrain cholinergic neurons. In adults, NGF is a key mediator of nociceptive sensitisation and inflammatory and chronic pain: it is upregulated at sites of injury and inflammation, sensitises peripheral nociceptors, and modulates mast-cell and immune-cell activity, which is the rationale for anti-NGF antibodies.

Beta-NGF, Beta-nerve growth factor, NGFB

Detects human NGF

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Tanezumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Tanezumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Tanezumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Tanezumab that binds human NGF.